TegoScience (A191420) Stock Overview
A biotechnology-based cosmetics company, engages in the production of various skin cell therapy products originating from human epithelial cells in South Korea. More details
| Snowflake Score | |
|---|---|
| Valuation | 0/6 |
| Future Growth | 0/6 |
| Past Performance | 0/6 |
| Financial Health | 5/6 |
| Dividends | 0/6 |
A191420 Community Fair Values
Create NarrativeSee what others think this stock is worth. Follow their fair value or set your own to get alerts.
Looking to be second time lucky with a game-changing new product
Key Takeaways Unicycive has successfully completed clinical development of its lead asset, Oxylanthanum Carbonate (OLC). OLC has been designed to improve on current phosphate binders by offering better efficacy, fewer pills, and improved tolerability over alternative treatments for hyperphosphatemia chronic kidney disease patients on dialysis.Read more
TegoScience Inc. Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | ₩14,170.00 |
| 52 Week High | ₩20,500.00 |
| 52 Week Low | ₩13,000.00 |
| Beta | 0.94 |
| 1 Month Change | -1.60% |
| 3 Month Change | -17.18% |
| 1 Year Change | -29.50% |
| 3 Year Change | 13.00% |
| 5 Year Change | -48.47% |
| Change since IPO | -8.73% |
Recent News & Updates
Is TegoScience (KOSDAQ:191420) Weighed On By Its Debt Load?
Jan 28
Is TegoScience (KOSDAQ:191420) Using Debt In A Risky Way?
Sep 01Recent updates
Is TegoScience (KOSDAQ:191420) Weighed On By Its Debt Load?
Jan 28Is TegoScience (KOSDAQ:191420) Using Debt In A Risky Way?
Sep 01We Think That There Are Some Issues For TegoScience (KOSDAQ:191420) Beyond Its Promising Earnings
Mar 28Are TegoScience Inc.'s (KOSDAQ:191420) Mixed Financials The Reason For Its Gloomy Performance on The Stock Market?
Feb 16How Much Of TegoScience Inc. (KOSDAQ:191420) Do Insiders Own?
Jan 12
Did You Miss TegoScience's (KOSDAQ:191420) Impressive 137% Share Price Gain?
Dec 08Shareholder Returns
| A191420 | KR Biotechs | KR Market | |
|---|---|---|---|
| 7D | -0.4% | 1.7% | -0.7% |
| 1Y | -29.5% | 47.0% | 101.9% |
Return vs Industry: A191420 underperformed the KR Biotechs industry which returned 47% over the past year.
Return vs Market: A191420 underperformed the KR Market which returned 101.9% over the past year.
Price Volatility
| A191420 volatility | |
|---|---|
| A191420 Average Weekly Movement | 6.4% |
| Biotechs Industry Average Movement | 9.8% |
| Market Average Movement | 6.4% |
| 10% most volatile stocks in KR Market | 13.0% |
| 10% least volatile stocks in KR Market | 2.9% |
Stable Share Price: A191420 has not had significant price volatility in the past 3 months compared to the KR market.
Volatility Over Time: A191420's weekly volatility (6%) has been stable over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 2001 | 40 | Saewha Jeon | www.tegoscience.com |
TegoScience Inc., a biotechnology-based cosmetics company, engages in the production of various skin cell therapy products originating from human epithelial cells in South Korea. The company offers Holoderm, a commercialized cultured skin autograft; Kaloderm, an allogeneic cell therapy product for healing wounds; Rosmir, a fibroblast cell therapy; and Neoderm, a three-dimensionally cultured skin model. It also provides KCM for skin regeneration effect; Chemotide, a single-chain human peptide; contract research services, such as biologics quality control services and histology services; and SkinBank, an insurance for cells.
TegoScience Inc. Fundamentals Summary
| A191420 fundamental statistics | |
|---|---|
| Market cap | ₩113.45b |
| Earnings (TTM) | -₩3.25b |
| Revenue (TTM) | ₩6.15b |
Is A191420 overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| A191420 income statement (TTM) | |
|---|---|
| Revenue | ₩6.15b |
| Cost of Revenue | ₩1.93b |
| Gross Profit | ₩4.22b |
| Other Expenses | ₩7.47b |
| Earnings | -₩3.25b |
Last Reported Earnings
Sep 30, 2025
Next Earnings Date
n/a
| Earnings per share (EPS) | -405.74 |
| Gross Margin | 68.62% |
| Net Profit Margin | -52.78% |
| Debt/Equity Ratio | 27.0% |
How did A191420 perform over the long term?
See historical performance and comparisonCompany Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2026/02/12 12:41 |
| End of Day Share Price | 2026/02/12 00:00 |
| Earnings | 2025/09/30 |
| Annual Earnings | 2024/12/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* Example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.
Analyst Sources
TegoScience Inc. is covered by 1 analysts. 0 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
| Analyst | Institution |
|---|---|
| Seung-Ho Lee | NH Investment & Securities Co., Ltd. |